Bio-Thera Solutions, a clinical-stage biopharmaceutical company developing a pipeline of innovative therapies and a pipeline of biosimilars, today announced the company will present two posters at the 2018 San Antonio Breast Cancer Symposium (SABCS) taking place December 4 - 8, 2018 in San Antonio, Texas.

The first poster, entitled “BAT8001, a potent anti-Her2 antibody-drug conjugate with a novel stable linker for the treatment of Her2-positive breast cancer,” will present preclinical data that highlight advantages of BAT8001 as a potential treatment for breast cancer patients. An abstract of the presentation is currently available on the SABCS website.

Presentation details are as follows:

The second poster, entitled “BAT8003, a potent anti-Trop-2 antibody-drug conjugate, for the treatment of Trop-2 positive Triple Negative Breast Cancer,” will present preclinical data that highlight advantages of BAT8003 as a potential treatment for triple negative breast cancer patients. An abstract of the presentation is currently available on the SABCS website.

Presentation details are as follows:

About BAT8001
BAT8001 is an investigational Her2-ADC being evaluated in multiple tumor types. Her2 is a naturally occurring receptor that is overexpressed in many types of cancer, including breast cancer and gastric cancer.  BAT8001 is being developed for use as a single agent and in combination with other agents for the treatment of multiple cancers. BAT8001 is currently being evaluated in a Phase 3 clinical trial for the treatment of metastatic breast cancer patients (more information on the trial is available at http://www.chinadrugtrials.org.cn/  (CTR20180157)).  The BAT8001 clinical study program will expand beyond metastatic breast cancer to other Her2-positive cancers, including gastric cancer, over the next 12 months.

About BAT8003

BAT8003 is an investigational Trop-2-ADC being evaluated in multiple tumor types. Trop-2 is a naturally occurring receptor that is overexpressed in many types of cancer, including triple negative breast cancer and gastric cancer.  BAT8003 is being developed for use as a single agent and in combination with other agents for the treatment of multiple cancers. A Phase 1 clinical trial evaluating the pharmacodynamics and safety of BAT8003 is scheduled to begin in 2019Q1.